...
首页> 外文期刊>Human Pathology >Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations
【24h】

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations

机译:一系列鼻窦原发性黑色素瘤中的癌基因异常:NRAS突变和细胞周期蛋白D1扩增比KIT或BRAF突变更常见

获取原文
获取原文并翻译 | 示例
           

摘要

Primary malignant melanoma of sinonasal tract is a rare but severe form of melanoma. We retrospectively analyzed 17 cases and focused on the histologic presentation and the expression of c-Kit, epidermal growth factor receptor (EGFR), cyclin D1/Bcl-1, PS100, and HMB45 and searched for BRAF, NRAS, and KIT mutations that are known to be associated with melanoma subtypes, together with amplifications of KIT, cyclin D1, cyclin-dependent kinase 4, MDM2, and microphthalmia-associated transcription factor using quantitative polymerase chain reaction. In most cases (78%), an in situ component was evidenced. Invasive components were composed of diffuse areas of rhabdoid, epithelioid, or spindle cells and, in most cases, lacked inflammatory reaction, suggesting that an immune escape phenomenon probably develops when the disease progresses. EGFR was rarely and weakly expressed in the in situ component of 2 cases. None of the investigated case showed BRAF V600E, but 1 had a D594G mutation. NRAS mutations in exon 2 (G12D or G12A) were found in 3 cases (18%), and a KIT mutation in exon 11 (L576P), in 1, whereas c-Kit was expressed at the protein level in half of the cases. Amplifications of cyclin D1 were evidenced in 5 cases, confirmed in 3 by fluorescence in situ hybridization, but this was not always correlated with protein expression, found in 8 patients (62.5%), 3 having no significant amplification. In conclusion, primary malignant melanoma of sinonasal tract is not associated with BRAF V600E mutations. Instead, NRAS or KIT mutations and cyclin D1 amplification can be found in a proportion of cases, suggesting that primary malignant melanoma of sinonasal tract is heterogeneous at the molecular level and should not be sensitive to therapeutic approaches aiming at BRAF.
机译:原发性鼻鼻窦恶性黑色素瘤是一种罕见但严重的黑色素瘤形式。我们回顾性分析了17例病例,重点研究了c-Kit,表皮生长因子受体(EGFR),细胞周期蛋白D1 / Bcl-1,PS100和HMB45的组织学表现和表达,并寻找了BRAF,NRAS和KIT突变已知与黑色素瘤亚型有关,并使用定量聚合酶链反应扩增了KIT,细胞周期蛋白D1,细胞周期蛋白依赖性激酶4,MDM2和小眼症相关转录因子。在大多数情况下(78%),有原位成分被证实。侵袭性成分由横纹肌,上皮样细胞或梭形细胞的扩散区域组成,并且在大多数情况下,缺乏炎症反应,这表明疾病发展时可能会产生免疫逃逸现象。在2例患者的原位组织中,EGFR很少且弱表达。所调查的病例均未显示BRAF V600E,但其中1例具有D594G突变。在3例(18%)中发现了外显子2(G12D或G12A)的NRAS突变,在1例中发现了外显子11的KIT突变(L576P),而在一半的情况下发现了c-Kit在蛋白质水平表达。在5例中证实了细胞周期蛋白D1的扩增,通过荧光原位杂交在3例中得到证实,但这并不总是与蛋白质表达相关,在8例(62.5%)中发现3例没有明显的扩增。总之,鼻窦道的原发性恶性黑色素瘤与BRAF V600E突变无关。相反,可以在一定比例的病例中发现NRAS或KIT突变和细胞周期蛋白D1扩增,这表明鼻窦道的原发性恶性黑色素瘤在分子水平上是异质的,并且对以BRAF为目标的治疗方法应不敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号